Theses›Healthcare & bio›Molecular biosensing
Molecular biosensing
Molecular biosensing: chip-scale detection of proteins, enzymes and biomarkers across transduction physics
- Early
- $5.5B by 2035
The call, a draftThe restraints are winning: chips that detect proteins and biomarkers keep improving, but the value goes to the regulated device, the assay and the surface chemistry. No chip-only supplier has reached venture scale, so the window is early.
- D1Magnetic biosensors are the fastest-growing readout at about 13.7% a year, from $1.12B in 2024 toward $3.66B in 2033.
- D2Photonic chips are reachable through foundry multi-project wafers, and the optical chip slice grows about 20% a year from about $0.5B in 2025.
- D3European teams keep choosing to sell the sensor die into other companies' cleared devices, including a multi-analyte photonic die made at TU Delft.
- R1No merchant biosensor chip supplier selling to instrument makers has reached venture scale, and the companies that got furthest moved forward into the device.
- R2The hard part sits in surface chemistry, binding and releasing the tracer on the detection surface, more than in the readout.
- R3Glucose dominates electrochemical biosensors and its chips are locked to Abbott, Dexcom and Roche supply chains.
- C1A European photonic biosensor chip supplier raises €5M or more at the chip layer.31 Dec 2027
Rests onthe beliefs underneath
Supported by · confidence
What would prove itdated tests, open and resolved
- 1Any magnetic or electrochemical chip supplier reaching venture scale selling the sensor itself.Dec 2030 · open
- 2First off-chip signal from an ensemble of 500-5,000 enzymes read on a magnetic chip.Dec 2030 · open
Expressionslisted, private, technologies
Private · 1 private company.
Lithic
6 more private companies tracked, not shown